Solana (HSDT) Stock Price, News & Analysis

Company Overview

Helius Medical Technologies, Inc. (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics. Frameworks of care vary by region but typically involve coordinated therapy protocols that combine the wearable stimulator, physical exercises and clinician-led monitoring. Helius supports its clinical users with training, device management and remote patient engagement tools to optimize rehabilitation outcomes.

Beyond its core PoNS offering, Helius is advancing an at-home digital therapy program that integrates software-guided exercises and telehealth support. The company collaborates with research institutions and rehabilitation centers to broaden the evidence base for its technology and explore applications in conditions such as mild traumatic brain injury, multiple sclerosis and stroke recovery. Ongoing clinical studies aim to expand indications and refine therapy protocols.

Founded in 2015 and headquartered in Toronto, Ontario, Helius Medical Technologies is led by President and Chief Executive Officer Dan M. Toutant. Since its inception, the company has pursued regulatory clearances across key markets and built partnerships with rehabilitation specialists to bring neuromodulation therapies to patients worldwide.

Key Stats

• Today's Range: $1.67 to $1.73
• 50-Day Range: $1.27 to $2.36
• 52-Week Range: $1.19 to $25.50
• Volume: 99,888 shs
• Average Volume: 161,058 shs
• Market Capitalization: $99.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Moderate Buy

Solana Stock Analysis - MarketRank™

Solana scored higher than 65% of companies evaluated by MarketBeat, and ranked 248th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Solana has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Solana has a consensus price target of $3.50, representing about 105.9% upside from its current price of $1.70.

Amount of Analyst Coverage

Solana has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Solana are expected to grow in the coming year, from ($0.09) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Solana is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Solana is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Solana has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.33% of the float of Solana has been sold short.

Short Interest Ratio / Days to Cover

Solana has a short interest ratio ("days to cover") of 5.11.

Change versus previous month

Short interest in Solana has recently decreased by 13.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Solana does not currently pay a dividend.

Dividend Growth

Solana does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.23

News Sentiment

Solana has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Solana this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Solana insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.40% of the stock of Solana is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

18.63% of the stock of Solana is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 7/30/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:HSDT
• CIK: 1610853
• Web: heliusmedical.com
• Phone: (877) 564-0008
• Fax: N/A
• Employees: 30
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Solana: $3.50
• High Price Target: $4.00
• Low Price Target: $3.00
• Potential Upside/Downside: +105.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($109.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.89 million
• Net Margins: -1,427.15%
• Pretax Margin: -1,427.17%
• Return on Equity: -67.57%
• Return on Assets: -24.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.90
• Quick Ratio: 9.90

Sales & Book Value

• Annual Sales: $6.02 million
• Price / Sales: 16.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.88 per share
• Price / Book: 0.25

Miscellaneous

• Outstanding Shares: 58,390,000
• Free Float: 49,979,000
• Market Cap: $99.26 million
• Optionable: Not Optionable
• Beta: 1.03